Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12449639 | 0.95 | KDM4E (0.45) | HRH3KEAP1SMN1; SMN2KDM4E | |
| SCHEMBL13433 | 0.95 | KDM4E (0.45) | HRH3KEAP1SMN1; SMN2KDM4E | |
| SCHEMBL13017 | 0.95 | KDM4E (0.45) | HRH3KEAP1SMN1; SMN2KDM4E | |
| SCHEMBL9374424 | 0.87 | HRH3 (0.53) | HRH3MAOBHRH2HRH1KDM4E | |
| SCHEMBL12449699 | 0.83 | KDM4E (0.45) | HRH3CYP1A2CYP2D6KEAP1SMN1; SMN2 | |
| SCHEMBL12995 | 0.83 | KDM4E (0.45) | HRH3CYP1A2CYP2D6KEAP1SMN1; SMN2 | |
| SCHEMBL1430617 | 0.83 | KDM4E (0.45) | HRH3CYP1A2CYP2D6KEAP1SMN1; SMN2 | |
| SCHEMBL12942 | 0.83 | KDM4E (0.50) | HRH3HRH2HRH1KDM4E | |
| SCHEMBL12449677 | 0.83 | KDM4E (0.50) | HRH3HRH2HRH1KDM4E | |
| SCHEMBL12666 | 0.81 | KDM4E (0.49) | HRH3CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488525-B1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS INC (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-9193731-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | HRH3 3537/4885CYP1A2 1366/4885CYP2D6 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.